Pharmaceutical News

RSS

Revlimid results look promising for multiple myeloma patients

The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.

8 Mar 2005

Battle in the Senate over FDA

In the congressional battle over the safety of America's prescription drugs, two University of Washington experts with opposing views have been enlisted into the fray.

7 Mar 2005

Neuren and Metabolic collaborate to develop range of nerve repair compounds

Neuren Pharmaceuticals Ltd (Neuren) and Metabolic Pharmaceuticals Ltd (Metabolic) have announced that the two companies have agreed to collaborate to co-develop Neuren's class of Neuro-regenerative Peptides (NRPs) for the treatment of degenerative conditions such as peripheral neuropathy, motor neuron disease and repairing the brain or nerves after injuries such as spinal cord injury.

7 Mar 2005

International expert group discusses alternatives to COX-2 inhibitors

International group of pain specialists meets to develop recommendations for the treatment of chronic moderate-to-severe pain in the wake of the global withdrawal of rofecoxib (Vioxx) and concerns regarding use of other COX-2 inhibitors.

7 Mar 2005

Opportunities for European pharmaceutical and biotechnology companies in Indian and Chinese markets

Despite having over a third of the world's population, Asia accounts for only one fifth of global pharmaceutical drug consumption. As income levels rise, demand from this large population base is set to burgeon, opening up new growth opportunities for pharmaceutical and biotechnology companies.

7 Mar 2005

Australian biotech, Bionomics acquires central nervous system (CNS) business

Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.

6 Mar 2005

Batches of the drugs Paxil and Avandamet seized by federal officials

Batches of the drugs Paxil CR and Avandamet United States, were seized by marshals at manufacturing and distribution plants in Tennessee and Puerto Rico after federal officials said the manufacturer failed to correct violations of production safety standards.

5 Mar 2005

FDA has accepts new drug application for Exubera (inhaled human insulin powder)

Dr. John Patton, co-founder and chief scientific officer for Nektar reported that Pfizer and The Sanofi-Aventis Group have announced that the FDA has accepted for filing a new drug application for Exubera (inhaled human insulin powder).

3 Mar 2005

Antidepressants prescribed to children will have Black Box labels warnings

Antidepressants prescribed to children should have "Black box" labels warnings, which are reserved for the most dangerous drugs, of the increased risk of suicide that they pose. This will happen mid-March, five months after the Food and Drug Administration ordered it.

3 Mar 2005

FDA issues information on the risks and benefits of Crestor

The U.S. Food and Drug Administration (FDA), today issued public health advice, patient information, and professional healthcare information on the risks and benefits of Crestor (Rosuvastatin calcium), a cholesterol-lowering drug.

2 Mar 2005

FDA wants full authority to control labeling for drugs

Sandra L. Kweder, FDA's deputy director for new drugs, wants Congress to issue the FDA with the authority to control labeling for drugs to stop the prolonged disputes on this matter.

2 Mar 2005

UK Government stockpiles anti-viral medicine Tamiflu from Roche

In an attempt to prevent the spread of the influenza pandemic birdflu the U.K. government will buy 200 million pounds ($384 million) worth of the anti-viral medicine Tamiflu from Roche, one of Switzerland's largest drug companies. The influenza pandemic could kill more than 50,000 people in the country.

1 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005

New cancer drug Avastin keeps cancer under control

Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps cancer under control for a significantly longer duration, even when used in a group of elderly patients with advanced colorectal cancer who are too sick to tolerate traditional aggressive chemotherapy.

1 Mar 2005

Aggressive industry promotion of prescription drugs may be a danger to patients and doctors

Vioxx, Celebrex and Bextra hit the market in the late 1990s & 2001, as a breakthrough class of drugs for arthritis that would help avoid ulcers and other digestive ailments linked to medicines such as aspirin.

28 Feb 2005

Wyeth advances diet drug settlement discussions

Wyeth has announced that plaintiffs' attorneys representing a substantial number of claimants who have opted out of the National Diet Drug Settlement have agreed to participate in a proposed process for settling downstream opt-out cases, and that the Company is prepared to move forward with the process.

28 Feb 2005

Fear of botulism as a bioterrorist weapon is to be reduced by British vaccine technology

Fear of botulism as a bioterrorist weapon is to be reduced, as the US government announces its support for a new British vaccine technology, which promises for the first time to provide an effective defence against botulism – the most deadly naturally occurring substance.

28 Feb 2005

New compounds for the treatment of HIV/AIDS

Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.

27 Feb 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Caution against FDA approval of race-based pharmaceutical

New York University Sociologist Troy Duster concludes that a pharmaceutical to combat heart disease among blacks is based on faulty research and urges the Food and Drug Administration to obtain more reliable data before approving the drug.

27 Feb 2005